BIO-BBIO-BNYSE
Loading
EBITDA Over TimeExpanding
Percentile Rank79
5Y CAGR-30.1%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

5Y CAGR
-30.1%/yr
Long-term compound
Percentile
P79
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$845.60M+139.5%
2024$-2.14B-227.1%
2023$-654.80M+85.4%
2022$-4.49B-180.3%
2021$5.59B+10.0%
2020$5.08B+106.5%
2019$2.46B+264.4%
2018$674.72M+150.3%
2017$269.52M+30.6%
2016$206.40M-